- Home
- ANGO vs VNDA Comparison
ANGO vs VNDA Comparison
Compare ANGO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- VNDA
- Stock Information
- Founded
- ANGO 1988
- VNDA 2002
- Country
- ANGO United States
- VNDA United States
- Employees
- ANGO N/A
- VNDA N/A
- Industry
- ANGO Medical/Dental Instruments
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- VNDA Health Care
- Exchange
- ANGO Nasdaq
- VNDA Nasdaq
- Market Cap
- ANGO 279.1M
- VNDA 282.8M
- IPO Year
- ANGO 2004
- VNDA 2006
- Fundamental
- Price
- ANGO $9.01
- VNDA $4.98
- Analyst Decision
- ANGO Strong Buy
- VNDA Strong Buy
- Analyst Count
- ANGO 3
- VNDA 2
- Target Price
- ANGO $13.00
- VNDA $16.50
- AVG Volume (30 Days)
- ANGO 513.8K
- VNDA 751.6K
- Earning Date
- ANGO 04-03-2025
- VNDA 05-07-2025
- Dividend Yield
- ANGO N/A
- VNDA N/A
- EPS Growth
- ANGO N/A
- VNDA N/A
- EPS
- ANGO N/A
- VNDA N/A
- Revenue
- ANGO $286,498,000.00
- VNDA $198,772,000.00
- Revenue This Year
- ANGO N/A
- VNDA $14.36
- Revenue Next Year
- ANGO $6.63
- VNDA $44.53
- P/E Ratio
- ANGO N/A
- VNDA N/A
- Revenue Growth
- ANGO N/A
- VNDA 3.18
- 52 Week Low
- ANGO $5.26
- VNDA $3.71
- 52 Week High
- ANGO $13.50
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- ANGO 39.09
- VNDA 58.23
- Support Level
- ANGO $8.27
- VNDA $4.84
- Resistance Level
- ANGO $9.44
- VNDA $5.10
- Average True Range (ATR)
- ANGO 0.47
- VNDA 0.24
- MACD
- ANGO -0.02
- VNDA 0.02
- Stochastic Oscillator
- ANGO 40.00
- VNDA 76.40
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.